



Cancer Research

Latest Update 11/10/2025

Cancer

- The LSU School of Veterinary Medicine (SVM) is pleased to announce a funding opportunity through the NIH-funded **Center for Pre-Clinical Cancer Research (CPCCR)** COBRE program. They are soliciting applications for 1–2 full projects as Principal Junior Investigators (PJIs) for the period **March 1, 2027 – February 28, 2030**.
 - **Key Details:**
 - **Eligibility:** LSU, SUBR, Pennington, and LSU Health New Orleans faculty (assistant professors in tenure-track positions preferred).
 - **Funding:** \$150,000 per year (direct costs) for up to 3 years.
 - **Proposal Type:** NIH R21-style full project application, including face page, budget, and preliminary results to support competitiveness for NIH R21/R01 funding.
 - **Deadline:** **December 15, 2025**
 - **Contacts:**
 - Dr. Joseph Francis, PI – jfrancis@lsu.edu
 - Dr. Gus Kousoulas, Co-I – vtgusk@lsu.edu
 - Applicants are encouraged to contact the PI or Co-I before submission to ensure project eligibility. Full instructions and

guidelines are available at [NIH R21 Funding](#). Please also review the attached for additional information.

- This is an exciting opportunity to advance cancer research in Louisiana using pre-clinical cancer models and to strengthen your NIH funding portfolio.
- **NCI, Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)** ([PAR-25-336](#)). **Expiration Date: November 16, 2027.**
- **NCI, Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)** ([PAR-25-106](#)). **Expiration Date: May 05, 2026.**
- **NCI, Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)** ([PAR-25-175](#)). **Expiration Date: January 08, 2028.**
- **NCI, NIAAA, Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)** ([PAR-25-221](#)). **Expiration Date: January 08, 2027.**
- **NCI, Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)** ([PAR-25-167](#)). **Expiration Date: January 08, 2027.**
- **NCI, Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)** ([PAR-24-304](#)). **Expiration Date: October 15, 2026.**
- **NCI, National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)** ([PAR-25-081](#)). **Expiration Date: January 08, 2027.**
- **NCI, Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)** ([PA-25-172](#)). **Expiration Date: January 08, 2028.**
- **NCI, Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)** ([PAR-24-311](#)). **Expiration Date: January 08, 2028.**

- **NCI, Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional) [PAR-25-043](#), (R21 Clinical Trial Not Allowed) [PAR-25-044](#). Expiration Date: January 08, 2028.**
- **NIH, Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) ([PAR-25-095](#)); (R21 Clinical Trials Not Allowed) ([PAR-25-096](#)). Expiration Date: September 08, 2026.**
- **NCI, Co-infection and Cancer (R01 Clinical Trial Not Allowed) ([PAR-25-082](#)); (R21 Clinical Trial Not Allowed) ([PAR-25-083](#)). Expiration Date: January 08, 2026.**
- **NCI, NCI Small Grants Program for Cancer Research (NCI Omnibus) (R03 Clinical Trial Optional) ([PAR-25-078](#)). Expiration Date: January 08, 2026.**
- **NCI, Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional) ([PAR-25-069](#)); (R21 Clinical Trial Not Allowed) ([PAR-25-070](#)). Expiration Date: January 08, 2027.**
- **NCI, Exploratory Grants in Cancer Control (R21 Clinical Trial Optional) ([PA-25-253](#)). Expiration Date: September 08, 2028.**
- **NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) ([PA-25-304](#)). Expiration Date: January 8, 2028.**
- **NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required) ([PA-25-306](#)). Expiration Date: January 8, 2028.**
- **NCI, Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional) ([PAR-25-103](#)); (R34 Clinical Trials Optional) ([PAR-25-104](#)). Expiration Date: October 26, 2027.**
- **NCI Pathway to Independence Award (K99/R00 Clinical Trial Not Allowed) ([PAR-25-135](#)). Expiration Date: October 15, 2027.**
- **NCI, Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed) ([PAR-25-074](#)), (UH3 Clinical Trials Not Allowed) ([PAR-25-075](#)). Expiration Date: October 15, 2026.**

- **AACR, American Association for Cancer Research Funding Opportunities.**

Details.

- AACR-Mark Foundation Chemistry in Cancer Research Grants
 - Letter of Intent Deadline: **December 16, 2025**
- AACR-Think Forward Foundation Career Development Award
 - Letter of Intent Deadline: **December 18, 2025**
 - Application Deadline: **April 7, 2026**
- Breast Cancer Research Foundation-AACR Career Development Awards
 - Letter of Intent Deadline: **December 16, 2025**
 - Application Deadline: **April 7, 2026**
- Breast Cancer Research Foundation-AACR NextGen Grant for Transformative Cancer Research in Honor of Nancy E. Davidson, MD
 - Letter of Intent Deadline: **December 18, 2025**
 - Application Deadline: **April 7, 2026**
- Breast Cancer Research Foundation and Lobular Breast Cancer Alliance-AACR Career Development Award
 - Letter of Intent Deadline: **December 16, 2025**
 - Application Deadline: **April 7, 2026**
- AACR-QuadW Foundation Sarcoma Research Fellowship in Memory of Willie Tichenor
 - Application Deadline: **November 18, 2025**